Exploring kidney health in patients after liver transplantation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate the prevalence and risk factors associated with the progression of renal function in patients who have undergone liver transplantation and are experiencing renal impairment. Approximately 369 participants will be enrolled, all of whom will have received a renal biopsy within the past three months. The study will collect data on demographic characteristics, medical history, and laboratory parameters, with participants followed for 96 weeks to monitor renal function and treatment outcomes. Standard care will be provided based on the pathological results of the biopsies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* age 18-75 years
* patients received liver transplantation
* new onset of proteinuria(defined as 24-hour proteinuria\>1g/24h, or Urinary albumin creatinine ratio(UACR)\>300mg/g on at least two occasions), and/or renal impairment: eGFR \<60 mL/min/1.73 m² at least two occasions, and/or serum creatinine increase ≥50% from baseline
* have received renal biopsy in the past 3 months
* Signed informed consent form(ICF)

Exclusion Criteria:

* patients received renal transplantation
* hepatic failure
* severe bleeding risk or platelet \<70\*109/L
* chronic kidney insufficiency with eGFR\<30ml/min·1.73m2,or kidney atrophy, or solitary kidney, or medullary sponge kidney, or polycystic kidney, or obstructive nephropathy
* uncontrolled mental disease or unable to cooperate during operation
* Pregnancy or lactation
* not suitable for this study judged by investigaters

Where it's running

• Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine
  Shanghai, China Recruiting
• Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine
  Shanghai, China Not yet recruiting

Study contacts

• Study coordinator: Shan Mou, Dr
• Email: shan_mou@126.com
• Phone: 13918221242

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Clazakizumab for adults with high hsCRP at risk for a heart event

  This study tests whether clazakizumab can lower inflammation and reduce cardiovascular risk in adults with high hsCRP and existing risk factors.

  Recruiting at 32 sites Phase 2 Eli Lilly and Company · Huntsville, Alabama and 45 other locations · NCT07783802

• Everolimus-based calcineurin-free immunosuppression one year after liver transplant

  This trial tests whether switching to or using everolimus with reduced calcineurin inhibitors after year one post-liver transplant can protect kidney function while maintaining graft health in adults at low rejection risk.

  Recruiting Phase 3 Hannover Medical School · Heidelberg, Baden-Wurttemberg and 15 other locations · NCT07739914

• Living with CKD as a woman of childbearing age without dialysis or transplant

  This study asks how women aged 18 and up with chronic kidney disease, not on kidney replacement therapy, experience living with the condition.

  Recruiting University Hospital, Caen · Caen · NCT07690202

• Sleep quality and its determinants during the liver transplant pathway

  This study tests how sleep quality changes from before liver transplantation to six months after, in adults on the transplant waitlist at a single hospital.

  Recruiting Hospices Civils de Lyon · Lyon · NCT07674355

• Preoperative CIMT and Intraoperative Hemodynamics in Liver Transplant

  This study looks at whether a higher carotid IMT measured before surgery is linked to more unstable blood pressure during liver transplant.

  Recruiting Dicle University · Diyarbakır · NCT07660679

• Balcinrenone plus dapagliflozin vs dapagliflozin alone in CKD stages 3b-4

  This study tests whether balcinrenone combined with dapagliflozin works better than dapagliflozin alone in adults with CKD stage 3b–4.

  Recruiting at 33 sites Phase 3 AstraZeneca · Huntsville, Alabama and 477 other locations · NCT07624305

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.